文献速递胸部肿瘤

第九版TNM分期系统在手术切除的非小细胞肺癌患者中的验证

Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer.
PubMed 文献 · Eur J Cancer · 2025-04-15

本研究回顾性分析7429例完全切除并行系统淋巴结清扫的非小细胞肺癌患者,验证第九版TNM分期系统并与第八版比较区分能力。中位随访50.4个月,第九版临床及病理分期的相邻分期组生存曲线均有显著差异,且区分能力优于第八版(C-index 0.769 vs 0.767,AIC 26,820 vs 26,851,R2 0.164 vs 0.160)。

要点

  • 第九版TNM分期在手术切除NSCLC中临床及病理分期相邻组生存均有显著差异。
  • 第九版区分能力优于第八版:C-index 0.769 vs 0.767,AIC 26,820 vs 26,851,R2 0.164 vs 0.160。
  • 共分析7429例患者,中位随访50.4个月(四分位距18-69个月)。

核心结论

  • 与第八版TNM分期系统相比,第九版对临床和病理分期的预后准确性更高、区分能力更优。

研究设计与样本

  • 回顾性分析纳入7429例(男性4325例;四分位距57-70岁)接受完全切除及系统淋巴结清扫的非小细胞肺癌患者。
  • 采用Cox回归模型识别相邻TNM分期组间的显著差异,计算C-index、AIC和R2评估两种分类系统的区分能力。

主要发现

  • 中位随访50.4个月(四分位距18-69个月)。
  • 按第九版分期的相邻分期组生存曲线在临床分期或病理分期下所有组均显示显著差异。
  • 第九版较第八版C-index更高(0.769 vs 0.767)、AIC更低(26,820 vs 26,851)、R2更高(0.164 vs 0.160)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The ninth edition of the tumor, node, and metastasis (TNM) classification system was recently published by the International Association for the Study of Lung Cancer staging project. This study aimed to validate the ninth edition of the TNM staging system, and compare its discrimination power with that of the eighth edition. METHODS: Patients who had undergone complete resection with systematic lymph node dissection for non-small cell lung cancer (NSCLC) were included in this retrospective analysis. Significant differences among adjacent TNM stage groupings were identified using a Cox regression model. The concordance index (C-index), Akaike Information Criterion (AIC), and R2 were calculated to assess the discriminatory power of the two classification systems. RESULTS: A total of 7429 patients (4325 male; interquartile range, 57-70 years) were analyzed. The median follow-up duration was 50.4 months (interquartile range, 18-69 months). Survival curves within adjacent stage groupings created according to the ninth edition exhibited significant differences for all groups when divided according to the clinical or pathological stage. Compared with that of the eighth edition, the ninth edition demonstrated an improved discriminatory ability, as evidenced by a higher C-index (0.769 vs. 0.767), lower AIC (26,820 vs. 26,851), and higher R2 (0.164 vs. 0.160) values. CONCLUSIONS: Compared to the eighth edition of the TNM staging system, the ninth edition demonstrated improved prognostic accuracy and superior discriminatory ability for clinical and pathological stages.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim S, Ahn Y, Lee GD, et al. Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer. Eur J Cancer. 2025. PMID: 40252632. doi:10.1016/j.ejca.2025.115436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。